Theriva Biologics, Inc.: Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
- Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma - - Dosed the first patient